Literature DB >> 22881829

Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.

Chien-Chi Tseng1, San-Ni Chen, Jiunn-Feng Hwang, Chun-Ju Lin.   

Abstract

The authors report refractive errors possibly resulting from intravitreal bevacizumab injection. Triplet A presented with stage 3 retinopathy of prematurity, was treated with intravitreal bevacizumab, and high refractive errors were noted. Triplet B presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which regressed spontaneously. Triplet C presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which were treated with intravitreal bevacizumab. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22881829     DOI： 10.3928/01913913-20120731-03

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN： 0191-3913            Impact factor:   1.402


  4 in total

1.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.

Authors:  Y-H Chen; S-N Chen; R-I Lien; C-P Shih; A-N Chao; K-J Chen; Y-S Hwang; N-K Wang; Y-P Chen; K-H Lee; C-C Chuang; T-L Chen; C-C Lai; W-C Wu
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

2.  Development of refractive error in individual children with regressed retinopathy of prematurity.

Authors:  Jingyun Wang; Xiaowei Ren; Li Shen; Susan E Yanni; Joel N Leffler; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-05       Impact factor: 4.799

3.  Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity.

Authors:  Chun-Ju Lin; Yi-Yu Tsai
Journal:  Clin Ophthalmol       Date:  2016-07-21

4.  Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.

Authors:  Qing-Qing Tan; Stephen P Christiansen; Jingyun Wang
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.